Evidence map›Paper›PMID 26608314›Full record

ArticleJournal of virology2016

Directed Molecular Evolution of an Engineered Gammaretroviral Envelope Protein with Dual Receptor Use Shows Stable Maintenance of Both Receptor Specificities.

Kristina Pagh Friis, Xavier Iturrioz, Jonas Thomsen, Rodrigo Alvear-Perez, Shervin Bahrami, Catherine Llorens-Cortes, Finn Skou Pedersen

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Kristina Pagh FriisDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris, France.
Xavier IturriozLaboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris, France Center for Interdisciplinary Research in Biology (CIRB), Collège de France, Paris, France CNRS, UMR 7241, Paris, France.
Jonas ThomsenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Rodrigo Alvear-PerezLaboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris, France Center for Interdisciplinary Research in Biology (CIRB), Collège de France, Paris, France CNRS, UMR 7241, Paris, France.
Shervin BahramiDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark SKAUvaccines, Aarhus, Denmark.
Catherine Llorens-CortesLaboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050, Paris, France Center for Interdisciplinary Research in Biology (CIRB), Collège de France, Paris, France CNRS, UMR 7241, Paris, France.
Finn Skou PedersenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark fsp@mb.au.dk.
Aarhus University · DKCentre National de la Recherche Scientifique · FRCollège de France · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledWe have previously reported the construction of a murine leukemia virus-based replication-competent gammaretrovirus (SL3-AP) capable of utilizing the human G protein-coupled receptor APJ (hAPJ) as its entry receptor and its natural receptor, the murine Xpr1 receptor, with equal affinities. The apelin receptor has previously been shown to function as a coreceptor for HIV-1, and thus, adaptation of the viral vector to this receptor is of significant interest. Here, we report the molecular evolution of the SL3-AP envelope protein when the virus is cultured in cells harboring either the Xpr1 or the hAPJ receptor. Interestingly, the dual receptor affinity is maintained even after 10 passages in these cells. At the same time, the chimeric viral envelope protein evolves in a distinct pattern in the apelin cassette when passaged on D17 cells expressing hAPJ in three separate molecular evolution studies. This pattern reflects selection for reduced ligand-receptor interaction and is compatible with a model in which SL3-AP has evolved not to activate hAPJ receptor internalization. IMPORTANCE: Few successful examples of engineered retargeting of a retroviral vector exist. The engineered SL3-AP envelope is capable of utilizing either the murine Xpr1 or the human APJ receptor for entry. In addition, SL3-AP is the first example of an engineered retrovirus retaining its dual tropism after several rounds of passaging on cells expressing only one of its receptors. We demonstrate that the virus evolves toward reduced ligand-receptor affinity, which sheds new light on virus adaptation. We provide indirect evidence that such reduced affinity leads to reduced receptor internalization and propose a novel model in which too rapid receptor internalization may decrease virus entry.

Indexed as

Directed Molecular EvolutionGenomic InstabilityViral TropismVirus InternalizationAnimalsApelin ReceptorsCell LineGammaretrovirusHumansReceptors, G-Protein-CoupledReceptors, VirusViral Envelope ProteinsXenotropic and Polytropic Retrovirus ReceptorApelin ReceptorsAPLNR protein, humanReceptors, G-Protein-CoupledReceptors, VirusViral Envelope ProteinsXenotropic and Polytropic Retrovirus ReceptorXPR1 protein, human

Identifiers

PMID26608314
PMCPMC4719614
OpenAlexW2173147222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.